MedTrace Logo

Platinum-Resistant, Recurrent Epithelial Ovarian Cancer

NCT00484666 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-09-16

No results posted yet for this study

Summary

Primary objective:

To estimate the overall clinical response rate (CR, PR, SD) of weekly docetaxel and weekly topotecan in women with recurrent platinum resistant ovarian or primary peritoneal cancer.

Secondary objectives:

To access the safety and tolerability of this novel combination chemotherapy regimen of weekly docetaxel and weekly topotecan in women with recurrent platinum resistant ovarian or primary peritoneal cancer

To estimate the progression free survival (PFS) and overall survival (OS) for women with recurrent platinum resistant ovarian or primary peritoneal cancer treated with this weekly docetaxel and weekly topotecan.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Dennis R Scribner, JR, MD · Carilion Clinic

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00484666 on ClinicalTrials.gov